Analysis and data insight

Cancer-cell-destruction-by-nanoparticles

Over the speed bump

Biopharmas developing cancer drugs whipsaw into 2020

February 18, 2020

The BioWorld Cancer index, which includes 21 representative companies developing therapies targeting various cancers, entered the new year on a high note, after posting a 22.5% gain for the year. Unfortunately, the group hit a speed bump and the index took a beating in January, dropping almost 9% as a result.

Week in review for Feb. 10-14, 2020: Candidate therapies hit speed bumps

February 18, 2020

By Peter Winter

No Comments

A quick look back at top stories, including: Advaxis, Avrobio, Beam, Biohaven, Blue Water, CNS, Collegium, Cortexyme, Deciphera, Eli Lilly, Genprex, Gibson, I-Mab, Inato, Logicbio, Moderna, Personalis, Promedior, Revance, Revolution, Roche, Syros, Theravance, Xeris, WPD.

Money raised by biopharma: 2020 vs. 2019

February 14, 2020

No Comments

Total raised in public, private and other financings of biopharma companies, comparing 2020 vs. 2019.

Biopharma money raised: Jan. 1-Feb. 13, 2020

February 14, 2020

No Comments

Year-to-date money raised in public, private and other financings of biopharma companies.

Regulatory submissions, approvals and other actions: January 2020

February 14, 2020

No Comments

Regulatory decisions affecting biopharma products in development, including: Abbvie, Aimmune, Alkermes, Alnylam, Amarin, Biohaven, Biolinerx, Blueberry, Clovis, Cytodyn, Durect, Emergent, Evoke, Exelixis, Fate, F-star, Galapagos, Genmab, Horizon, Incyte, Ipsen, Janssen, Jubilant, Mesoblast, Nabriva, Nektar, Nicox, Orion, Pharmacyte, Pharming, Pulmatrix, Recordati, Regeneron, Seelos, Sorrento, Ultragenyx, Vistagen.

Biggest gainers and losers for the week of Feb. 10-14, 2020

February 14, 2020

No Comments

The top 10 biopharma stock gainers and losers for the week.

Med-tech gainers and losers for Feb. 10-14, 2020

February 14, 2020

No Comments

The top 10 med-tech stock gainers and losers for the week.

Multiple spin-offs in the works

Pharmas break up to accelerate growth

February 11, 2020

By Brian Orelli

No Comments

Even as the volume of mergers and acquisitions in 2019 reached the highest level in the last 10 years, multiple big pharma companies are looking to get smaller, spinning off units into separate entities.

AI partnerships ‘move the industry forward’

Trial recruitment, retention improved but drop-outs persist in late studies

February 11, 2020

By Marie Powers

No Comments

Multiple tactics employed by the biopharma industry to improve the recruitment and retention of participants in clinical trials seem to be paying off. More than three of four (77%) studies now fully enroll on or ahead of schedule, according to researchers at the Tufts Center for the Study of Drug Development (CSDD), reporting in the January/February Tufts CSDD Impact Report on global recruitment performance benchmarks.